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In the Western countries cardiovascular disease and cancer are the leading causes of death in 
the ageing population. Recent epidemiological data suggest that cancer is more frequent in 
patients with prevalent or incident cardiovascular disease, in particular heart failure. Indeed, 
there is a tight link in terms of shared risk factors and mechanisms between heart failure and 
cancer. Heart failure induced by anticancer therapies has been extensively studied, primarily 
focusing on the toxic effects that antitumor treatments exert on cardiomyocytes. In this Cardio-
Oncology update, members of the ESC WGs of Myocardial Function and of Cellular Biology 
of the Heart discuss novel evidence interconnecting cardiac dysfunction and cancer via 
pathways in which cardiomyocytes may be involved, but are not central. In particular, the 
multiple roles of cardiac stromal cells (endothelial cells, fibroblasts) and inflammatory cells are 
highlighted. Also, the gut microbiota is depicted as a new player at the crossroads between heart 
failure and cancer. Finally, the role of non-coding RNAs in Cardio-Oncology is also addressed. 





















In the industrialized world, cardiovascular (CV) disease and cancer are the leading 
causes of death in the ageing population 1. Left ventricular dysfunction (LVD) and heart failure 
(HF) are not rare across the broad population of cancer patients. In cancer patients, CV disease 
is the most frequent non-cancer cause of death 2. HF and cancer share the same risk factors (e.g. 
ageing, smoking, obesity, diabetes, dyslipidemia, alcohol intake, inflammation)  3, 4. 
Furthermore cancer and HF may have ancillary factors linking the two together 5. Registries 
have observed that HF patients have a higher cumulative incidence of cancer, with a worse 
prognosis when both co-exist 6, suggesting that cancer surveillance may be useful in the 
management of HF patients 7. Finally, an increased cumulative incidence of cancer among HF 
patients 30 days after MI has been reported, compared to HF-free patients 30 days after MI 8.  
When considering these observations, it should be taken into account that there may be 
a surveillance bias, due to the fact that these study patients usually undergo an intense follow-
up program that may lead to anticipate cancer diagnosis, sometimes discovering malignancies 
that would have gone undiscovered. Moreover, some of the most common therapies used to 
treat HF patients may play a role in revealing tumors otherwise asymptomatic (e.g. a latent 
intestinal neoplasm can bleeding due to anti-thrombotic therapy)3. Clinical presentations can 
also be difficult to distinguish between HF and cancer, since the 2 conditions can share some 
common symptoms (fatigue, dyspnea, weight loss, muscle wasting, oedema) 1, 3. This may delay 
the diagnosis of new-onset cancer in HF patients due to the overlap in clinical manifestation. 
Furthermore, CV function and predictors of exercise capacity have been shown to be impaired 
in patients with cancer per se9. Hence, symptoms due to a tumor may overlap with those of HF 
and be attributed to heart disease. This may even delay cancer diagnosis, as symptoms might 
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between cancer and HF is not well-defined in clinical studies, there are increasing data to 
suggest mechanistic links between the two conditions that we discuss in our manuscript. 
Beside these reciprocal relations, cancer and HF carry an independent risk of mortality 
and also limit optimal treatment of the other condition when they co-exist, contributing to 
higher mortality. In addition, the cardiotoxicity risk related to treatment with anticancer drugs 
may unmask or deteriorate pre-existing HF 3. The mechanisms driving HF triggered by 
anticancer therapies have been extensively investigated over the last 20 years and important 
insights have been uncovered 10-12. Nonetheless, major questions are still open, and the answers 
to these questions may lay the foundations for new strategies to detect, monitor and treat cancer-
therapy induced cardiotoxicity. On the other hand, research into the common pathways linking 
cancer and HF regardless of anticancer drugs has just begun 13. 
The latest insights in translational Cardio-Oncology were discussed during the joint 
meeting of the Working Groups of Myocardial Function and the WG of Cellular Biology of the 
Heart of the European Society of Cardiology, held in Naples, Italy, in May 2019. In particular, 
given the systemic involvement of both HF and cancer, the Cardio-Oncology session focused 
on the contribution of organs, systems and cells other than cardiomyocytes to the pathogenesis 
of cardiac dysfunction in cancer patients, and to the interconnection between cancer and HF, 
primarily via inflammation. Opportunities and the current limitations in the use of microRNAs 
(miRNA) in cardio-oncology were also discussed. These topics are reviewed here, to provide 
the reader with updated information and further stimulate research in the field. 
 
2. Role of non-cardiomyocytes in cancer treatment-related cardiotoxicity 
The heart is a multicellular organ composed by cardiomyocytes, fibroblasts, neurons, 
endothelial and hematopoietic-derived cells. In fact, cardiomyocytes are not the most abundant 
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through complex intercellular communications 15. Most studies performed so far have focused 
on the effects of anticancer drugs on cardiomyocytes, in both in vitro systems and in vivo models 
16 (see table 1). Briefly, among the many forms of cardiotoxicity caused by several anticancer 
drugs (table 2), cardiac dysfunction due anthracyclines such as doxorubicin (DOXO) has 
historically been the most relevant 17. From a pathophysiological point of view, anthracyclines 
induce cardiomyocyte death, mainly apoptosis and necrosis, via different molecular 
mechanisms, including but not limited to induction of oxidative stress, activation of DNA 
damage responses and impairment of mitochondrial biogenesis and metabolism 18-20. Among 
other mechanisms involved in anthracycline-induced cardiotoxicity, abnormalities in 
myocardial energetics have slso been studied 21, 22. Also biological drugs, designed to target 
specific oncologic pathways may be cardiotoxic, since these pathways play a major role in the 
maintenance of cardiac homeostasis, especially  during stressful conditions, such as 
hypertension or hypertrophy 23. For instance, human epidermal growth factor receptor 2 
(HER/ErbB2) and angiogenesis inhibitors profoundly affect cardiomyocytes metabolism and 
contractile proteins, as discussed in comprehensive reviews 16, 24-26.  
In addition, antitumor therapies likely also affect non-cardiomyocytes in the heart. For 
instance, DOXO has been shown to exert toxic effects on cultured cardiac endothelial cells 27 
and fibroblasts 28-30. This direct activity on non-cardiomyocytes may partly account for the 
cardiotoxicity of the drug, e.g. endothelial cells lose their barrier function with increased 
permeability and myocardial injury.  
The impact of the toxicity of  DOXO and any other antitumor treatment on non-
cardiomyocytes can be better understood when it is placed into the context of the intercellular 
cross-talks in the heart. This concept is exemplified by the current knowledge about the 
cardiotoxicity of anti-HER2 drugs 31. Besides being expressed in breast cancer cells, 
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tyrosine kinases (RTK) of the same family, HER4/ErbB4 32. Upon binding of HER4/ErbB4 by 
neuregulin-1 (NRG) and other ligands secreted by cardiac microvascular endothelial cells, 
HER2/ErbB2 and HER4/ErbB4 form heterodimers and initiate protective signaling cascades. 
Therefore, drugs targeting HER/ErbB2 are postulated to disrupt the NRG1-HER2/ErbB2-
mediated endothelial cell-cardiomyocyte crosstalk and make cardiomyocytes more vulnerable 
to other stressors (Figure 1). It is notable that trastuzumab, used in the treatment of human 
epidermal growth factor receptor (HER)-2+ breast cancer, also directly damages 
cardiomyocytes and endothelial cells 33; 34. 
The inhibitors of the RTK for vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF)  cause cardiac microvascular dysfunction secondary to depletion 
of coronary microvascular pericytes 35. The resulting myocardial hypoxia leads to sustained 
expression of hypoxia-inducible factor alpha (HIF-), which was demonstrated to be sufficient 
to cause cardiomyopathy 36,37. Indeed, enhanced vascular permeability and reversible 
microvascular vasoconstriction have been reported in patients receiving therapies targeting 
VEGF and PDGF receptor (VEGFR and PDGFR, respectively) 38. Moreover, this mechanism 
of toxicity well explains the clinical observation that cardiomyopathy associated with anti-
VEGFR/PDGFR agents is reversible 39. 
However, evidence obtained over the last years suggests that blockade of VEGF 
signaing also interrupt endothelial cell-cardiomyocyte communication (Figure 1). VEGF binds 
VEGFR on endothelial cells to stimulate angiogenesis, but also to induce the release of 
angiocrines (including ErbB4 and ErbB1 ligands) that modulate the function and homeostasis 
of adjacent cardiomyocytes 40. Thus, drugs that inhibit VEGFR may alter cardiac function by 
interfering with the VEGF-VEGFR signaling axis, as well as by promoting endothelial cell 
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targeting VEGFR2 and PDGFR as the most toxic in human induced pluripotent stem cell 
(hiPSC)–derived endothelial cells 43. 
Experimental models and analyses of human biopsies indicate that some features of HF 
with preserved ejection fraction (HFpEF) are at least in part driven by cardiac endothelial cell 
dysfunction. This latter elicits inflammatory infiltration of the myocardium, fibroblasts 
activation to deposit collagen excessively and increased stiffness triggered by a reduction of 
nitric oxide-dependent signaling 44-46. Consistently with the epidemiological finding that the 
risk of HFpEF is correlated with prior radiotherapy for breast cancer 47, similar features were 
demonstrated in rats receiving cardiac radiation 48. Since non-proliferating cardiomyocytes are 
considered resistant to ionizing radiation, other cell types, and in particular endothelial cells, 
are predicted to be the main target of radiation therapy leading leads to HF 49.  
Fibroblasts also regulate cardiomyocytes and inflammatory cells through their 
secretome 50, 51. In a recent study, DOXO caused both apoptosis of cardiac fibroblasts and 
secretion of Fas ligand, which in turn promoted cardiomyocyte death in a paracrine manner 52. 
Conditional deletion of ataxia telangiectasia mutated kinase (ATM) in cardiac fibroblasts 
attenuated cardiac cell apoptosis, LVD and mortality in response to DOXO, suggesting that 
fibroblast are central in the pathogenesis of DOXO cardiotoxicity through ATM. The 
interactions between fibroblasts and other cardiac cell types, and the mechanisms in the 
cardiotoxicity of anticancer therapies, are an important area for future research 52. Senescence 
of fibroblasts and possibly other cardiac stromal cells is especially worth being investigated, 
since it has been proposed that it plays a major role in the pathogenesis of heart disease 53.  
In conclusion, oncological drugs and radiotherapy induce abnormalities in non-
cardiomyocytes, which secondarily derange the networks with cardiomyocytes and may lead to 
LVD and HF. Additional studies are needed, 54, 55 also considering that cardiotoxicity may be 
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heart 56. Since cardiac diseases and their comorbidities significantly change the global cardiac 
transcriptome, proteome and metabolome, it is not surprising that several drugs may act 
differently on the diseased versus healthy hearts 57, 58. Novel cardiac safety testing platforms 
involving combined experimental models of cardiac diseases in the presence and absence of 
major cardiovascular co-morbidities and/or co-treatments are needed 59. In this regard, cardiac 
organoids may allow modelling the complexity of the interactions between the different cardiac 
cell populations and, thereby, comprehensively evaluate the effects of anticancer therapies 55. 
 
3. Interconnections between cancer and heart failure 
Recently, attention has been drawn to the fact that cancer and heart disease have a 
reciprocal relationship: while the presence of cancer may cause LVD, the presence of HF 
associates with excess incident cancer 3-5, 60. The communication between these two threatening 
diseases is complex, intriguing and involves many components. 
First, during life and aging, several risk factors accumulate, which lead to chronic 
inflammation, oxidative stress, and protein and DNA instability. Classical CV risk factors, 
including obesity, diabetes, dyslipidemia and inflammation, are also associated with the 
development of cancer. Many of these risk factors lead to accumulation of fat mass, which is 
an active endocrine organ, secreting inflammatory factors and adipokines, which in turn have 
been associated with new onset CV disease (CVD) and new onset cancer 3-5, 60. 
Second, genetic mutations that accumulate throughout life, such as clonal hematopoiesis 
of indeterminate potential (CHIP), defined as the presence of clonal leukocytes with impaired 
immune proprieties derived by acquired mutation in hematopoietic stem cells, have been 
associated with both cancer and CVD, including HF 61-65. These mutations usually occur in a 
few genes, including DNMT3A, TET2, ASXL1, PPM1D, JAK2, TP53, SF3B1, and SRSF266. 
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of hematologic malignancies, it seems to be tightly linked to increased CV events and worse 
HF prognosis61-65, 67.  
Also, genetic mutations in sarcomeric proteins predispose to HF in patients undergoing 
chemotherapy. Unrecognized rare variants in cardiomyopathy-associated genes, particularly 
Titin truncating variants, have been shown to increase the risk for systolic dysfunction and 
cardiac events in a relatively small population of both children and adults undergoing 
chemotherapy. In specific populations, genotype variant testing, along with cumulative 
chemotherapy dosage and traditional cardiovascular risk factors, may be useful to improve the 
identification of cancer patients with a higher risk for developing HF upon chemotherapy 68. 
Other CV risk factors, such as hypertension and trace albuminuria, have been related to 
cancer development. Therefore, systemic risk factors likely exert effects on several damage 
pathways, and it is hypothesized that individual additional risk factors, such as genetic 
predisposition or pre-existing conditions, will also contribute to the risk of one or both 
conditions. 
Third, cancer and CVD are both associated with profound changes in tissue structure, 
either growth of entirely new tissue or tissue deformation, remodeling, and scarring of pre-
existing tissues, such as heart, endothelial cells and matrix.  Neoplasms are characterized by 
stroma, which is matrix tissue supporting the tumor, providing a scaffold, structure, and 
connections to adjacent organs. Further, most cancers, and especially metastases, rely on strong 
neovascularization requiring mitogenic endothelial cells and pericytes, where multiple growth 
factors play a role. In comparison, damaged cardiac tissue leads to dysfunctional 
cardiomyocytes, and also may develop extracellular matrix remodeling, fibrosis and scar. 
Matrix is produced by activated fibroblasts and multiple cell types homing in, including 
monocytes, macrophages and neutrophils. The cardiac scar is not a static structure, but rather 










4. Psychological convergence of HF and cancer 
There is a well established psychological impact on patients suffering from chronic 
conditions, notably heart failure. This is one of the main aims of cardiac rehabilitation 
programmes in these patients. Unfortunately, rehabilitation programmes have only recently 
been implemented in cancer patients, in a generic “one fits all” umbrella rather than bespoke 
guidelines for specific cancers. It is notable however, the recognition that both cardiac 
dysfunction syndromes and cancers have a significant impact in regards to neuronal changes. 
Whilst these have only just been thought of, the molecular and cellular mechanisms of neuro-
biology change remain relatively unknown. It is likely that both neuronal changes per se as well 
as modifications in signaling and transmission underlie the clinical states of depression or 
cognitive changes in these patients. The most likely culprit remains the chronic systemic 
inflammatory state present in both, probably responsible for an enhanced level of oxidative 
stress, DNA damage, mitochondrial dysfunction as well as synaptic modifications 70; 71. 
Whilst there is available evidence to support a link between certain chemotherapies and 
peripheral neuropathy (for example cisplatin), the issue of clinical states of depression/cognitive 
changes and them per se being a basis for autonomic dysfunction seen in these patients is far 
more complex and yet undemonstrated. At this current time it does not have the level of 
evidence and merrits further exploration. 
 
5. Inflammation at the crossroad between cancer, cardiotoxicity of anticancer 
therapies and heart failure 
Abnormal inflammation is increasingly recognized as a common driver of CVD and 
cancer 72, 73. HF is characterized by a state of mild chronic systemic inflammation, with 
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factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). Myocardial injury itself 
triggers the recruitment and the activation of immune cells, which in turn produce pro-
inflammatory cytokines and contribute to a self-perpetuating inflammatory state that underlies 
adverse tissue remodeling, primarily associated with capillary dysfunction and fibrosis 74. 
Doxorubicin-induced damage also involves inflammation (Figure 2), with upregulation of pro-
inflammatory toll-like receptor 4 (TLR4) in macrophages 75, higher levels as TNF-α and IL-6 
and reduced levels of the anti-inflammatory cytokine IL-10 76. Cardiac function was preserved 
and survival improved in TLR2 knock-out mice after DOXO exposure compared to wild-types 
77. DOXO also induces local modulators of inflammation and fibrosis, produced by both 
macrophages and fibroblasts. Increased production of the matricellular protein 
thrombospondin-2 (TSP2) is protective in mice treated with DOXO. Enhanced myocyte 
damage in the absence of TSP-2 was associated with impaired activation of the Akt signaling 
pathway. Inhibition of Akt phosphorylation in cardiomyocytes significantly reduced TSP-2 
expression, unveiling a unique feedback loop between Akt and TSP-2 78. Importantly, 
CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors is a 
desired therapeutic effect of anthracyclines 79. 
Indeed, for decades oncologists have been developing strategies to modulate 
inflammation in order to achieve therapeutic anticancer immune responses 80. The first attempts 
were not really successful, since cancer escapes T-cell-mediated cancer-specific immunity via 
inhibitory pathways mediated by cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), 
programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1) (all 
depressing the antineoplastic activity of T lymphocytes) 81. On the opposite, in the last years, 
Immune Checkpoint Inhibitors (ICIs), such as monoclonal antibodies (mAbs) targeting CTLA-
4, PD-1 and PD-L1, have dramatically improved the outcome of many malignancies, but serious 
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with the CTLA-4 and PD-1 axes can bring to autoimmune myocarditis and dilated 
cardiomyopathy85, suggesting that these molecules play an important  role in preventing 
autoimmunity86. Hence, immunosuppressive therapies may be necessary to halt immune related 
adverse events (IRAEs) and major adverse cardiovascular events (MACE) 87-89. 
More recently, engineered T cells with chimeric antigen receptors (CAR-T cells) have 
been approved by the U.S. Food and Drug Administration (FDA) as the first genetically 
modified autologous T-cell immunotherapeutic agents that target CD-19. CD-19 is broadly 
expressed on most B-cell malignancies and has limited expression beyond B-cell lineage 90, 91. 
Unfortunately, CAR-T cells are burdened by cytokine release syndrome (CRS) that is due to 
elevated levels of inflammatory cytokines released by activated CAR-T cells and other immune 
cells such as macrophages, with fever and tachycardia that may be associated with hypotension 
and hypoxia. Also, cardiac dysfunction and extremely serious complications such as vascular 
leak syndrome with circulatory collapse and multiorgan failure can be dreadful side effects of 
these therapies 92, 93 (Figure 2). Beside CAR-T cells, bispecific antibodies such as 
blinatumumab (that targets CD19 and CD3 and is increasingly used in the treatment 
of Philadelphia chromosome negative B cell acute lymphoblastic leukemia (ALL)) can also 
lead to CRS and cardiomyopathy94.  
Interestingly, inflammation in cancer plays a dual role. On the one hand it is essential to 
recognize and destroy cancer cells; on the other hand it provides a fertile milieu for 
tumorigenesis and plays key roles in different steps of tumor development, from initiation and 
promotion to invasion and metastasis. Tumor-associated inflammation favors proliferation and 
survival of malignant cells, promotes angiogenesis and metastasis, undermines adaptive 
immune responses, and potentially interferes with responses to hormones and chemotherapeutic 
agents 95, 96. The finding that anti-inflammatory agents are effective in the prevention of cancer 
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study concluded that chronic systemic low-grade inflammation, measured by CRP levels <10 
mg/L, is a risk factor for incident cancer, in particular lung cancer, in patients with stable CVD. 
The relation between inflammation and incident cancer is seen in former and current smokers 
and is uncertain in never smokers 97. Blockade of the pro-inflammatory cytokine IL-1β with 
canakinumab was shown to significantly reduce the rate of recurrent CV events in patients with 
previous myocardial infarction (CANTOS trial). At the same time, blocking IL-1β appeared to 
protect from lung cancer mortality 98, 99. Mice exposed to DOXO showed an increase in serum 
IL-1β along with other inflammatory factors 100. Moreover,  the IL-1β receptor antagonism 
protects against DOXO cardiotoxicity 101. Similarly, the IL-6 inhibitor tocilizumab can protect 
against MACE in CAR-T patients93. 
The experience of IL-1β blockade highlights that the identification of key players of the 
inflammatory response is important to tackle both cancer and heart disease. Among intriguing 
candidates are PI3Ks, and more specifically the PI3K isoform that is enriched in both 
cardiomyocytes and leukocytes (Figure 2). This implies a key role for this isoform not only in 
the control of cardiomyocyte pathobiology, but also in the orchestration of the inflammatory 
response associated to different types of cardiovascular injury 102. PI3K is upregulated in 
patients as well as in mouse models of atherosclerosis, and directs leukocyte infiltration of the 
arterial wall, which is a key pathogenic event in atherosclerosis103. PI3K-mediated 
inflammation is also pivotal to the cardiac response to pressure overload 104.  
Besides directing the cardiac response to stress, macrophage PI3K expression critically 
contributes to tumor growth and progression. Intriguingly, macrophages play opposite roles in 
non-oncological inflammatory conditions and cancer. In response to pathogens or injury, 
macrophages express cytokines that stimulate cytotoxic T cells to clear infected or damaged 
cells. Conversely, in cancer macrophages express anti-inflammatory cytokines that induce 
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immunotherapies (i.e. T cell checkpoint inhibitors). PI3K has been recently proposed as the 
molecular switch controlling immune stimulation and suppression in cancer 105. The unique 
feature of macrophage PI3K, playing a maladaptive role both in heart disease and in cancer, 
makes this enzyme the ideal pharmacological target to “kill two birds with one stone”, i.e. to 
halt the tumor and at the same time treat the heart 106. This is particularly relevant for cancer 
patients treated with chemotherapy and suffering from iatrogenic cardiotoxicity 15, 105 107. 
Results from clinical trials assessing the combined anticancer effect of such compounds in a 
context of cardiac protection are awaited. 
 
6. The gut microbiome in Cardio-Oncology 
HF has long been recognized to be associated with altered gut function 108, 109. Low 
cardiac output in HF results in intestinal ischaemia, with congestion of the splanchnic 
circulation, bowel wall oedema and impaired intestinal barrier function (Figure 3). This 
condition increases the overall inflammatory state as well as oxidative stress as a consequence 
of HF-induced ischaemia and congestion within the gut via enhanced bacterial translocation 
and the presence of bacterial products in the blood circulation. Increased leakiness modifies the 
gut environment and affects its resident microbial population 110. 
Among the conditions that can influence the gut composition, including individual 
genetic variability, lifestyle, colonization and delivery at birth 111-113, also changes in diet, 
presence of diseases and relative treatments have to be considered 114. Interestingly, genetic 
composition of gut microbiota, defined as microbiome, also influences cancer development and 
progression in different ways 115. Several types of cancers (head and neck, lung, colorectal and 
cervical carcinomas) promote a shift in microbiome composition 116-118. In addition, 
chemotherapy directly impacts the gut microbiota and its efficacy is strongly influenced by 
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Metabolites generated by the gut microbiota derive from the fermentation of indigestible 
fibres to short-chain fatty acids, that have protective properties (reducing inflammation, 
oxidative stress 121, 122 and improving vascular tone). Dietary sources of choline, 
phosphatidylcholine, l-carnitine, and other methylamine-containing nutrients provide 
substrates for microbiota-mediated generation of trimethylamine (TMA) that accesses the 
portal circulation and is converted by the hepatic flavin-containing monooxygenase (FMO) 
family of enzymes into trimethylamine N-oxide (TMAO, Table 3). TMAO can favor the 
development of atherosclerosis, thrombosis, kidney disease, and HF (Figure 3). High plasma 
levels of TMAO have been suggested to be predictive of cardiovascular events of mortality, 
independently from renal function and cardiovascular comorbitities110.  
Additionally, the bacterial transformation of bile acids can result in altered bile acid 
profiles, that in turn can impact systemic inflammatory and fibrotic processes 110. Importantly, 
microbiota-derived peptide mimics may also drive HF, by inducing a lethal inflammatory 
cardiomyopathy. Cardiac myosin-specific TH17 cells are being imprinted in the intestine by a 
commensal Bacteroides species peptide mimic. These cells promote cardiac inflammation and 
dysfunction in genetically susceptible individuals 123.  
Several studies reported SCFAs-producing bacteria perturbation in patients with CVDs 
124. Among these SCFA generated by the gut microbiota, butyrate (BUT) has multiple beneficial 
effects for our cardiovascular system through different mechanisms 125-131, 120 (Table 3). BUT 
exerts major epigenetic effects, acting as a potent inhibitor of histone deacetylase (HDACs) 
activity. Inhibition of HDACs is well-known to protect the heart from pathologic hypertrophy 
and ischaemia 132-135. Among HDAC inhibitors, BUT has been shown to exert anti-neoplastic 
properties in vitro 136, 120; while its derivatives can enhance the anticancer cytotoxic effects of 
DOXO while protecting against cardiotoxicity 137 and can decrease cardiac apoptosis and 
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apoptotic signalling and HDAC-inhibition mechanisms 138, 139. The cardioprotective effect of 
BUT and analogues is associated with the production of anti-inflammatory molecules, 
cytoprotection, modulation of angiogenesis, limiting the occurrence of cardiotoxic 
manifestations caused by DOXO treatments, with reduction of nitrosative and oxidative stress, 
counteracting mitochondrial dysfunction 121. In turn, DOXO is reported to induce GUT-
microbiota dysbiosis in mice, while the administration of BUT attenuates the inflammation state 
induced by DOXO 140, fuelling nutraceutical as a new promising area of research to cardio-
oncology   
 
7. Opportunities and limitations in the use of noncoding RNAs in Cardio-Oncology 
Multiple evidence seems to suggest an involvement of circulating microRNAs 
(miRNAs) in anthracyclines-induced cardiotoxicity both in vivo and in the clinical setting, 
evidencing a very heterogeneous situation. In particular, when focusing on DOXO, miR-1 141, 
142 and miR-34a 143-146, showed a drug-induced regulation in tissues and plasma samples, both 
in patients and animal models. miR-1 is one of the most investigated and most highly expressed 
miRNAs in cardiac and skeletal muscle, both in physiological 146, 147 and pathologic 148, 149 
condition. While many groups have indicated miR-1 as a specific circulating marker of heart 
disease, there is no clear indication about its unambiguous cardiac origin, particularly in 
anthracyclines-induced toxicity, which is a systemic phenomenon. Similarly, miR-34a was 
demonstrated to be modulated by anthracyclines both in experimental models 144, 145, 150 and in 
breast cancer patients 151. Piegari and co-authors, showed that tissue regulation of miR-34a by 
DOXO was not restricted only to the heart 144, hinting at a multi-tissue contribution to the 
circulating levels of this miRNA. Indeed, besides cardiomyocytes, smooth muscle cells, 
fibroblasts, cardiac progenitor cells and endothelial cells may also play a role in DOXO-induced 
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and VEGF-A expression with a parallel increase in miR-320a 153. Inhibition of miR320a 
improved cardiac function, decreased apoptosis, and increased microvessel density in DOXO-
treated mice, while overexpression of miR-320a worsened DOXO-induced LV dysfunction 154. 
Conversely, overexpression of the miR-320a target VEGF-A prevented detrimental effects of 
miR-320a in DOXO-cardiotoxicity experimental model confirming VEGF as a direct 
downstream target molecule 153. Mechanistically, the overexpression of the pro-hypertrophic 
miR-212/132 cluster in primary rodent and human iPSC-derived cardiomyocytes as well as in 
in vivo models has been shown to inhibit doxorubicin-induced toxicity 155 Also, another class 
of noncoding RNAs, circular RNAs, may play a crucial role in mediating cardiotoxicity of 
doxorubicin; indeed, overexpression of the RNA binding protein Quaking 5 (Qki5) strongly 
attenuated the toxic effect of doxorubicin in a mouse model by regulating a set of circular RNAs 
including those derived from titin (Ttn; 156). 
The role of miRNAs as markers of cardiotoxicity has also been investigated. Ruggeri 
and coworkers 150 showed that after one month from DOXO administration, only a part of the 
drug-treated mice presented cardiac dysfunction, similarly to the clinical context. miR-1 was 
again among the circulating miRNAs regulated after cardiotoxicity onset, together with miR-
499-5p. In an acute DOXO cardiotoxicity model, the same authors showed that miR-34a-5p 
and miR-451a were dysregulated in all cardiac chambers, with miR34a-5p showing opposite 
trends of regulation between the atria and the ventricles of treated mice. In another study using 
DOXO both in vivo and in vitro acutely and chronically  treated cardiomyocytes, DOXO-
dependent downregulation of miR-30 led to increased cardiomyocyte apoptosis and 
abnormalities of cardiomyocyte β-adrenergic receptor signaling 157. 
Importantly, only part of circulating miRNAs overlapped with their cardiac 
counterparts, suggesting only a partial contribution of the heart to the variations in circulating 
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animals, the number of screened miRNAs (often only selected cardiovascular miRNAs), the 
acute phase observed, the absence of tumor in the experimental models, and the lack of 
additional cancer treatments.  
Besides the few miRNAs showing a “reproducible sensitivity” to anthracycline 
treatment, there is a highly heterogeneous picture composed by past and present investigations. 
While the discrepancies in terms of results could be in part explained by the different 
experimental models and by the different malignancies and therapies adopted in patients-based 
investigations, there are at least two fundamental issues that should be addressed in future 
works. A striking feature of many, if not all, published papers is that no study described a 
decline of LVEF below the “normal” threshold of 50%, possibly because of lack of a long-term 
follow-up.  Moreover, the vast majority of human-based research studies concentrated on the 
acute phase of cardiotoxicity 158, and the same limitations often apply also to experimental 
researches, which rarely go beyond a few days’ time span from treatment to sacrifice.  
Additional data on the main non-coding RNAs are summarized in Table 4. 
 
8. Concluding remarks 
We discussed several of the novel exciting insights that are emerging in the ever-
expanding field of cardio-oncology. More research is required to identify and investigate the 
pathways and mechanisms underpinning the intimate relationship between CVD and cancer. 
Current studies focus on shared risk factors, both acquired/modifiable and genetic. The 
substantial structural changes in diseased organs prompt further studies in an effort to learn how 
disease in one organ may communicate with another organ. Learning from each disease 
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Figure legend.  
 
Figure 1 
Besides directly affecting cardiomyocytes and the other cardiac cell populations, cancer 
treatments may disrupt the intercellular communications between cardiomyocytes and non-
cardiomyocytes. The inset in the lower part of the Figure shows key endothelial cell (green)-
cardiomyocyte (red) paracrine signaling axes that may be impaired by antitumor therapies. 
NRG-1: neuregulin-1; VEGF: vascular endothelial growth factor; VEGFR2: vascular 
endothelial growth factor receptor type 2; NO: nitric oxide; cGMP: cyclic guanosine 
monophosphate; PKG: protein kinase G 
 
Figure 2 
Inflammation at the intersection of the anti-cancer action and cardiac side effects of major 
oncological treatments.  
Besides directly killing tumor cells, doxorubicin triggers cardiac inflammation via activation of 
macrophages and fibroblasts and the ensuing release of local modulators of inflammation and 
fibrosis, such as TNF-α, IL-1β and IL-6. Major players of the inflammatory response induced 
by doxorubicin include macrophage TLR-4, the matricellular protein thrombospondin-2 (TSP-
2) and leukocyte PI3K. On the other hand, immune check point inhibitors (ICIs) inhibit 
molecules such as cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell 
death 1 (PD-1) and its ligand PD-L1. As a consequence, anti-tumor immune cell responses are 
reactivated and lead to tumor cell death, but concomitantly drives myocarditis. Although these 
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resistance exist, and these might be overcome by using PI3K inhibitors that re-shape the tumor 
immune microenvironment. Finally, engineered T cells with chimeric antigen receptors (CAR-
T cells) boosts T cell-mediated tumor killing, but are burdened by cytokine release syndrome 
(CRS) leading to extremely serious complications, including cardiac and vascular dysfunction, 
and ultimately to multiorgan failure.  
 
Figure 3 
GUT Microbiome Dysbiosis can be influenced by both HF and cancer. HF has long been 
associated with congestion of splanchnic circulation, leading to bowel wall edema, impaired 
intestinal barrier function and increased systemic inflammation, that drastically affect GUT 
microbiome composition and response to HF treatments. At the same time, cancer-mediated 
disruption of metabolism and the production of cancer-derived metabolites modifies the 
microbiome. Such altered gut microbiome generates cardiotoxic metabolites such as TMAO 
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Table 1. Main direct toxic effects of cancer therapies on cardiomyocytes 
Cellular toxicity Treatment(s) most commonly involved 
Type II topoisomerase poisoning * Anthracyclines 
Mitochondrial dysfunction 
Anthracyclines, VEGFR / multitargeted RTK 
inhibitors 
Oxidative stress Anthracyclines 
Impaired authophagy Anthracyclines, proteasome inhibitors 
Altered protein handling Proteasome inhbitors 
Induction of HIF pathways VEGFR / multitargeted RTK inhibitors 
 
* This toxicity is peculiar of anthracyclines. 
VEGFR: vascular endothelial growth factor receptor; RTK: receptor tyrosine kinase; HIF: 
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Table 2. Cardiovascular toxicities of cancer therapies 
Type of toxicity Treatment(s) most commonly involved 
LVD, HF 
Anthracyclines, HER2-targeting drugs, VEGFR / 
multitargeted RTK inihibitors, proteasome inhibitors, 
radiation therapy (HFpEF) 
Myocardial ischemia Fluoropyrimidines, VEGFR inhibitors, radiation therapy 
Myocarditis ICIs, cyclophosphamide (rarely) 
Atrial fibrillation Ibrutinib 
QT prolongation 
Arsenic trioxide, vandetanib,androgen deprivation 
therapy (enzalutamide) 
Valvular heart disease radiation therapy 
Pericarditis ICIs,cyclophosphamide 
Hypertension VEGFR inhibitors 
Peripheral artery disease Nilotinib, ponatinib 
Vascular thrombosis * 
Cisplatin, nilotinib, ponatinib, thalidomide and 
lenalidomide, VEGFR inhibitors, proteasome inhibitors, 
aromatase inhibitors 
Pulmonary arterial hypertension Dasatinib, cyclophosphamide 
 
* Acute myocardial ischemia will ensue if thrombosis occurs at coronary artery atherosclerotic 
plaques. 
LVD: left ventricular dysfunction; HF: heart failure; VEGFR: vascular endothelial growth 
factor receptor; RTK: receptor tyrosine kinase; HFpEF: heart failure with preserved ejection 












Role of TMAO and Butyrate in Cardio-Oncology 
Cardiovascular field Cancer field 
TMAO Butyrate TMAO Butyrate 
Prognostic 5 years 
follow-up marker 
in patients with 
heart failure. 
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inhibition  leukemic 
cells proliferation;  
inhibition of Lewis 
lung carcinoma cells 
growth136 
 
Increase of the 
antineoplastic effect of 
DOXO137 
 
*High levels of TMAO in patients have been suggested to be predictive of cardiovascular events 
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Table 4 1309 
Non-coding RNAs in Cardio-Oncology 1310 
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